Two-year (mid-term) results for unprotected left main coronary artery percutaneous interventions with drug-eluting stents.

OBJECTIVE: Bypass surgery remains the revascularization strategy of choice for left main trunk coronary artery disease in an unselected group of patients. Drug eluting stents have been proposed as a viable alternative to bypass surgery for left main trunk lesions but their intermediate and long term outcomes are still under scrutiny. METHODS: A series of 50 patients with significant unprotected left main trunk stenosis (>50%) underwent revascularization with drug eluting stents (sirolimus and paclitaxel stents) and were enrolled in a registry. Follow up angiography was clinically driven. Recurrent chest pain and ischemia on myocardial perfusion imaging were clinical parameters that mandated repeat angiography. Prespecified primary endpoints of this registry were defined as major adverse cardiac event at 2 year follow up. RESULTS: No differences in outcomes were noted with either type of drug eluting stent used in this study (Sirolimus versus Paclitaxel). The low major adverse cardiac event rate of 14% at 2 years warrants a randomized control trial in a low surgical risk group of patients comparing bypass grafting with left main trunk percutaneous intervention. CONCLUSION: This registry confirms findings by other investigators about the safety of unprotected LMT stenting in an unselected group of patients. The acceptable MACE rate at 2 years from registries such as this suggests the need for a randomized control trial comparing the two strategies.

Tornus catheter facilitated recanalization of chronic total occlusions--another niche device for a difficult lesion subset.

One of the last frontiers facing interventionalists is the treatment of chronic total occlusions. Chronic total occlusions (CTO) are present in about one-third of all diagnostic coronary angiograms. Recanalizations of these CTOs have demonstrated a trend towards lower mortality. Unfortunately, use of standard angioplasty equipment has only resulted in a 50-60% success rate.5,6,7 Several recently developed guidewires have increased success rates to 79-90%. Further success in CTO revascularization has been improved by use of novel techniques such as crossing the lesion in a retrograde fashion from collateral vessels. Niche devices such as the Frontrunner CTO catheter (Lumend Inc., Johnson and Johnson, Picataway, NJ) have also facilitated in successful treatment of CTOs. Unfortunately, none of these developments address the issue of deliverability of angioplasty balloons and stents. A newly developed device, the Tornus catheter (Asahi Intech; Abbot Vascular, Redwood City, CA), plays a niche role in the recanalization of this lesion subset. The following contains two case reports which highlight successful revascularization of CTOs with utilization of this new catheter.